Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis

Pediatr Surg Int. 2014 Mar;30(3):323-6. doi: 10.1007/s00383-014-3477-y. Epub 2014 Jan 28.

Abstract

Purpose: Ceftriaxone has been associated with development of pseudolithiasis. In our institution, it is used for treatment of perforated appendicitis in children. This study evaluated the occurrence of ceftriaxone-related pseudolithiasis in this population.

Methods: After obtaining IRB approval, we performed a retrospective chart review over 51 months. We included patients undergoing laparoscopic appendectomy for perforated appendicitis. All patients were treated with ceftriaxone post-operatively. Patients without initial or post-treatment gallbladder imaging available for review were excluded.

Results: There were 71 patients who met inclusion criteria with a mean (±SD) age of 10.8 ± 3.8 years. Of these, 14 % (n = 10) developed stones or sludge in the gallbladder. The mean duration of ceftriaxone therapy was 8.7 ± 3.8 days. The average time to post-antibiotic imaging was 11.5 ± 10.3 days from initiation of antibiotics. There was no significant difference in duration of ceftriaxone therapy in the children that developed pseudolithiasis or sludge (10.0 ± 4.9 days) compared to those that did not (8.5 ± 3.6, p = 0.26). One child (10 %) with pseudolithiasis went on to become symptomatic, requiring a laparoscopic cholecystectomy.

Conclusions: In our experience, ceftriaxone use for perforated appendicitis is associated with a significant incidence of biliary pseudolithiasis, and is unrelated to duration of ceftriaxone therapy.

MeSH terms

  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Appendicitis / drug therapy*
  • Appendicitis / surgery*
  • Ceftriaxone / adverse effects*
  • Ceftriaxone / therapeutic use
  • Child
  • Cholelithiasis / chemically induced*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Retrospective Studies
  • Time Factors

Substances

  • Anti-Bacterial Agents
  • Ceftriaxone